PTC Therapeutics, Inc. PTCT closed lower on Thursday following the company’s decision to withdraw its New Drug Application for Translarna after receiving feedback from the U.S. Food and Drug ...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: ...
Zacks Investment Research on MSN
PTC Therapeutics (PTCT) expected to beat earnings estimates: What to know ahead of Q4 release
Wall Street expects a year-over-year increase in earnings on higher revenues when PTC Therapeutics (PTCT) reports results for the quarter ended December 2025. While this widely-known consensus outlook ...
PTC Therapeutics (NASDAQ: PTCT) reported fourth-quarter results that missed Wall Street expectations on both earnings and revenue, even as management pointed to strong momentum from the recent launch ...
Detailed price information for Ptc Therapeutics (PTCT-Q) from The Globe and Mail including charting and trades.
PTC Therapeutics Inc. reports fourth-quarter earnings after the market close Thursday, with investors eager to assess whether the company’s newly launched PKU treatment can offset a recent regulatory ...
CEO Matthew Klein highlighted 2025 as a year of “many significant successes,” citing the initial global approvals and launch of Sephience for PKU as the main highlight. Klein stated, “The global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results